Opinion|Videos|March 4, 2026
Systemic Therapy and Downstaging in Unresectable, Nonmetastatic HCC
Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss the use of systemic therapy to achieve downstaging in unreeseactable, nonmetastatic HCC.
Advertisement
Episodes in this series
Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, explore the evolving role of systemic therapy as a tool for downstaging disease. Chan reviews how immunotherapy-based combinations may increase the likelihood of tumor shrinkage sufficient to permit resection, transplantation, or ablation in selected patients. Cantis emphasizes careful patient selection and multidisciplinary evaluation when considering downstaging strategies, given variability in liver function and procedural eligibility.
Advertisement
Related to this article
RELATIVITY-1093 is comparing nivolumab and relatlimab plus chemotherapy vs pembrolizumab plus chemotherapy in PD-L1–positive nonsquamous NSCLC.
First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
P. Leia Nghiemphu, MD, discusses INTUITT-NF2 trial findings, the NCCN inclusion of brigatinib, and unmet needs in NF2-related schwannomatosis.
NEXERA-303 is evaluating INCA33890 plus FOLFOX and bevacizumab vs chemotherapy and bevacizumab alone in previously untreated MSS mCRC.
Biagio Ricciuti, MD, PhD, discusses Krascendo 1 data for divarasib, co-mutation–guided sequencing, and emerging RAS inhibitors in KRAS G12C–positive NSCLC.
Fox Chase researchers identified ANO6 as a potential pancreatic cancer target; blocking it slowed tumor growth and reduced immune suppression in preclinical studies.
Davide Melisi, MD, PhD, discusses INCB161734’s mechanism of action and the DAWN-303 trial design in KRAS G12D-mutated pancreatic cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dostarlimab Monotherapy Elicits Durable cCRs in dMMR/MSI-H Locally Advanced Rectal Cancer
2
NEXERA-303 Trial Aims to Bring TGFβR2×PD-1 Bispecific Antibody INCA33890 Into First-Line MSS CRC
3
The OncFive: Top Oncology Articles for the Week of 10/25
4
INCB161734 Combination Data Shape DAWN-303’s All-Comers Design in Frontline KRAS G12D-Mutated PDAC
5